Sugi Predict

Sugi Predict / Targets / APH1A

APH1A

Gamma-secretase subunit APH-1A (APH-1a) (Aph- · Q96BI3 · APH1A on Sugi Atlas →

142,169 patent compounds predicted against APH1A, 74,810 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL33171 SCHEMBL33171 1.00 20/20
SCHEMBL137789 SCHEMBL137789 1.00 20/20
SCHEMBL139302 SCHEMBL139302 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237758) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237759) 1.00 20/20
Mrk-560 Mrk-560 (SCHEMBL237760) 1.00 20/20
SCHEMBL136503 SCHEMBL136503 0.76 20/20
SCHEMBL154957 SCHEMBL154957 0.66 20/20
SCHEMBL138898 SCHEMBL138898 0.66 20/20
SCHEMBL139605 SCHEMBL139605 0.66 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL154119) 0.65 20/20
SCHEMBL139065 SCHEMBL139065 0.64 20/20
SCHEMBL151407 SCHEMBL151407 0.62 20/20
SCHEMBL138968 SCHEMBL138968 0.61 20/20
SCHEMBL139498 SCHEMBL139498 0.60 20/20
SCHEMBL154717 SCHEMBL154717 0.58 20/20
SCHEMBL139470 SCHEMBL139470 0.58 20/20
SCHEMBL139515 SCHEMBL139515 0.58 20/20
SCHEMBL139460 SCHEMBL139460 0.58 20/20
SCHEMBL155625 SCHEMBL155625 0.57 20/20

Clinical trials — most relevant to APH1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline PHASE4COMPLETED
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE) PHASE4COMPLETED
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. PHASE2/PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB PHASE2COMPLETED
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease PHASE1/PHASE2COMPLETED
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis PHASE1/PHASE2COMPLETED
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS) PHASE1/PHASE2COMPLETED
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
R21 Roche: 3-Way Tau Tracers in AD PHASE1ACTIVE_NOT_RECRUITING
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Late Onset Alzheimer's Disease nanRECRUITING
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
The Signature of Alzheimer's Disease in Subjective Cognitive Decline nanRECRUITING
Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients nanWITHDRAWN
Clearance Mechanisms in Atypical Neurodegenerative Diseases nanUNKNOWN
The Evaluation and Follow-up of Individuals With Memory Disorder nanCOMPLETED
Apolipoprotein E Gene and Functional MRI nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a APH1A binder may also engage these)

ProteinNameSimilarity
Q8BVF7 — 1.000 Q8BVF7 →
Q9DCZ9 — 0.999 Q9DCZ9 →
Q8C7N7 — 0.997 Q8C7N7 →
Q8JHE9 — 0.997 Q8JHE9 →
APH1B Gamma-secretase subunit APH-1B (APH-1b) (Aph- 0.993 landscape →
Q5RDM3 — 0.993 Q5RDM3 →
Q8L9G7 — 0.992 Q8L9G7 →
Q9VQG2 — 0.991 Q9VQG2 →
O45876 — 0.986 O45876 →
Q8BI36 — 0.982 Q8BI36 →
Q9P055 — 0.980 Q9P055 →
Q2TA63 — 0.979 Q2TA63 →
A2XX57 — 0.978 A2XX57 →
I6VSD2 — 0.977 I6VSD2 →
Q5U4Q2 — 0.977 Q5U4Q2 →
A0A8I3MKU8 — 0.977 A0A8I3MKU8 →
B4HEB1 — 0.976 B4HEB1 →
B4QPR1 — 0.976 B4QPR1 →
Q9CRG1 — 0.976 Q9CRG1 →
Q28FG4 — 0.976 Q28FG4 →
Q0V9G6 — 0.976 Q0V9G6 →
Q9CQG6 — 0.976 Q9CQG6 →
Q4KM77 — 0.976 Q4KM77 →
B4J2W3 — 0.975 B4J2W3 →
B4PF15 — 0.975 B4PF15 →
Q28FY5 — 0.975 Q28FY5 →
Q90ZE4 — 0.975 Q90ZE4 →
Q5FWM8 — 0.975 Q5FWM8 →
B3NGS7 — 0.975 B3NGS7 →
Q8QZR0 — 0.975 Q8QZR0 →